A May 12, 2025 Executive Order signed by President Trump directed the HHS Secretary to communicate “most favored nation” (“MFN”) price “targets” to pharmaceutical manufacturers. The same Executive Order also instructed the HSS Secretary to facilitate direct-to-consumer purchasing programs for pharmaceutical manufactures to sell drugs to patients at the MFN price. As of January 9, 2026, 15 of the 17 companies contacted after the Executive Order was issued had reached agreements with the current presidential administration. These actions, along with shifting tariff policies, have impacted and may continue to impact pharmaceutical imports and drug pricing.
All entries for: CAMP4 Therapeutics
March 4, 2026
CAMP4 Therapeutics
Neutral Outlook
Cambridge, MA
1-50 employees
Additionally, the Inflation Reduction Act of 2022 includes several provisions such as drug pricing controls and Medicare redesign that are likely to continue impacting our business to varying degrees, but we cannot predict the exact nature of its future effects on our business and the healthcare industry in general
Disease Area: Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic
April 30, 2025
CAMP4 Therapeutics
Neutral Outlook
Cambridge, MA
1-50 employees
Additionally, the Inflation Reduction Act of 2022 includes several provisions such as drug pricing controls and Medicare redesign that are likely to impact our business to varying degrees, but its ultimate effect on our business and the healthcare industry in general is not yet known
Disease Area: Cardiology, Metabolic Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule